Scientific Working Group on Dengue, 2007. Report of the Scientific Working Group on Dengue, 1–5 October 2006. Geneva: World Health Organization.
Gubler DJ, Clark GG, 1995. Dengue/dengue hemorrhagic fever: the emergence of a global health problem. Emerg Infect Dis 1: 55–57.
Guy B, Nougarede N, Begue S, Sanchez V, Souag N, Carre M, Chambonneau L, Morrisson DN, Shaw D, Qiao M, Dumas R, Lang J, Forrat R, 2008. Cell-mediated immunity induced by chimeric tetravalent dengue vaccine in naive or flavivirus-primed subjects. Vaccine 26: 5712–5721.
Sun W, Cunningham D, Wasserman SS, Perry J, Putnak JR, Eckels KH, Vaughn DW, Thomas SJ, Kanesa-Thasan N, Innis BL, Edelman R, 2008. Phase 2 clinical trial of three formulations of tetravalent live-attenuated dengue vaccine in flavivirus-naive adults. Hum Vaccine 4: 33–40.
Widdus R, 2005. Public-private partnerships: an overview. Trans R Soc Trop Med Hyg 99 (Suppl 1): S1–S8.
Pediatric Dengue Vaccine Initiative, 2006. Pediatric Dengue Vaccine Initiative. Available at: http://www.pdvi.org. Accessed January 22, 2010.
Sackett D, Straus S, Richardson W, Rosenberg W, Haynes R, 2000. Guidelines. Evidence-based Medicine: How to Practice and Teach EBM. Second edition. Edinburgh: Churchill Livingstone.
York Centre for Reviews and Dissemination, 2001. Report for undertaking systematic reviews of research on effectiveness. Available at: http://www.york.ac.uk/inst/crd/report4.htm. Accessed January 22, 2010.
Murray CJ, Lopez AD, 1994. Quantifying disability: data, methods and results. Bull World Health Organ 72: 481–494.
Anderson KB, Chunsuttiwat S, Nisalak A, Mammen MP, Libraty DH, Rothman AL, Green S, Vaughn DW, Ennis FA, Endy TP, 2007. Burden of symptomatic dengue infection in children at primary school in Thailand: a prospective study. Lancet 369: 1452–1459.
Añez G, Balza R, Valero N, Larreal Y, 2006. Economic impact of dengue and dengue hemorrhagic fever in the State of Zulia, Venezuela, 1997–2003 [Spanish]. Rev Panam Salud Publica 19: 314–320.
Armien B, Suaya JA, Quiroz E, Sah BK, Bayard V, Marchena L, Campos C, Shepard DS, 2008. Clinical characteristics and national economic cost of the 2005 dengue epidemic in Panama. Am J Trop Med Hyg 79: 364–371.
Arthur D. Little, Incorporated, 1992. The Prevention of Diseases Transmitted by Aedes aegypti in the Americas: A Cost-Benefit Study. Washington, DC: Pan American Health Organization.
Baly A, Toledo ME, Boelaert M, Reyes A, Vanlerberghe V, Ceballos E, Carvajal M, Maso R, La Rosa M, Denis O, Van der Stuyft P, 2007. Cost effectiveness of Aedes aegypti control programmes: participatory versus vertical. Trans R Soc Trop Med Hyg 101: 578–586.
Beutels P, Scuffham P, MacIntyre CR, 2008. Funding of drugs: do vaccines warrant a different approach? Lancet Infect Dis 8: 727–733.
Canyon DV, 2008. Historical analysis of the economic cost of dengue in Australia. J Vector Borne Dis 45: 245–248.
Cho-Min-Naing, 2000. Assessment of dengue hemorrhagic fever in Myanmar. Southeast Asian J Trop Med Public Health 31: 636–641.
Clark DV, Mammen MP Jr, Nisalak A, Puthimethee V, Endy TP, 2005. Economic impact of dengue fever/dengue hemorrhagic fever in Thailand at the family and population levels. Am J Trop Med Hyg 72: 786–791.
DeRoeck D, Deen J, Clemens JD, 2003. Policymakers' views on dengue fever/dengue haemorrhagic fever and the need for dengue vaccines in four Southeast Asian countries. Vaccine 22: 121–129.
Ferrando JE, 1995. Estimate of the Costs of the Dengue Epidemic in 1994 in Nicaragua: Consultancy Report. Washington, DC: Pan American Health Organization.
Garg P, Nagpal J, Khairnar P, Seneviratne SL, 2008. Economic burden of dengue infections in India. Trans R Soc Trop Med Hyg 102: 570–577.
Gubler DJ, Meltzer M, 1999. Impact of dengue/dengue hemorrhagic fever on the developing world. Adv Virus Res 53: 35–70.
Guzmán MG, Triana C, Bravo J, Kourí G, 1992. Estimation of the economic impact of the dengue hemorrhagic fever epidemic in Cuba, 1981 [Spanish]. Rev Cubana Med Trop 44: 13–17.
Harling R, Crook P, Lewthwaite P, Evans M, Schmid ML, Beeching NJ, 1999. Burden and cost of imported infections admitted to infectious disease units in England and Wales in 1998 and 1999. J Infect 48: 139–144.
Harving ML, Rönsholt FF, 2007. The economic impact of dengue hemorrhagic fever on family level in Southern Vietnam. Dan Med Bull 54: 170–172.
Huy R, Wichmann O, Beatty M, Ngan C, Duong S, Margolis HS, Vong S, 2009. Cost of dengue and other febrile illnesses to households in rural Cambodia: a prospective community-based case-control study. BMC Public Health 9: 155–162.
Jacobs B, Price N, 2004. The impact of the introduction of user fees at a district hospital in Cambodia. Health Policy Plan 19: 310–321.
Khun S, Manderson L, 2007. Health seeking and access to care for children with suspected dengue in Cambodia: an ethnographic study. BMC Public Health 7: 262.
LeDuc JL, Esteves K, Gratz NG, 2004. Dengue and dengue hemorrhagic fever. The global epidemiology of infectious diseases. Murray CJ, Lopez LD, Mathers CD, eds. Global Burden of Disease and Injury Series, Volume IV. Geneva: World Health Organization.
Lok CK, 1985. Singapore's dengue haemorraghic fever control programme: a case study on the successful control of Aedes aegypti and Aedes albopictus using mainly environmental measures as a part of an integrated vector control. Tokyo: Southeast Asian Medical Information Center.
Lum LC, Suaya JA, Lian HT, Sah BK, Shepard DS, 2008. Quality of life of dengue patients. Am J Trop Med Hyg 78: 862–867.
Luz PM, Grinsztejn B, Galvani AP, 2009. Disability adjusted life years lost to dengue in Brazil. Trop Med Int Health 14: 237–246.
McConnell KJ, Gubler DJ, 2003. Guidelines on the cost-effectiveness of larval control programs to reduce dengue transmission in Puerto Rico. Rev Panam Salud Publica 14: 9–16.
Meltzer MI, Rigau-Pérez JG, Clark GG, Reiter P, Gubler DJ, 1998. Using disability-adjusted life years to assess the economic impact of dengue in Puerto Rico: 1984–1994. Am J Trop Med Hyg 59: 265–271.
Ministry of Health Brazil, 2002. National Program for Control of Dengue. Portuguese. Brasilia. Available at: http://portal.saude.gov.br/portal/arquivos/pdf/pncd_2002.pdf. Accessed January 22, 2010.
Nathan MB, 1993. Critical review of Aedes aegypti control programs in the Caribbean and selected neighboring countries. J Am Mosq Control Assoc 9: 1–7.
Okanurak K, Sornmani S, Indaratna K, 1997. The cost of dengue hemorrhagic fever in Thailand. Southeast Asian J Trop Med Public Health 28: 711–717.
Orellano PW, Pedroni E, 2008. Cost-benefit analysis of vector control in areas of potential dengue transmission [Spanish]. Pan Am J Public Health 24: 113–119.
Osaka K, Ha DQ, Sakakihara Y, Khiem HB, Umenai T, 1999. Control of dengue fever with active surveillance and the use of insecticidal aerosol cans. Southeast Asian J Trop Med Public Health 30: 484–488.
Palanca-Tan R, 2008. The demand for a dengue vaccine: a contingent valuation survey in Metro Manila. Vaccine 26: 914–923.
Pan American Health Organization, 1997. The feasibility of eradicating Aedes aegypti in the Americas. Pan Am J Public Health 1: 68–72.
Pan American Health Organization, 1997. Hemispheric plan to expand and intensify efforts to combat Aedes aegypti (OPS/HCP/HCT/90/97). Washington, DC: Pan American Health Organization. Available at: http://www.paho.org/English/AD/DPC/CD/doc406.pdf. Accessed January 22, 2010.
Shepard DS, Halstead SB, 1993. Dengue (with notes on yellow fever and Japanese encephalitis). Jamison DT, Mosley WH, Measham AR, Bobadilla JL, eds. Disease Control Priorities for Developing Countries. New York: Oxford University Press for the World Bank.
Shepard DS, Suaya JA, Halstead SB, Nathan MB, Gubler DJ, Mahoney RT, Wang DN, Meltzer MI, 2004. Cost-effectiveness of a pediatric dengue vaccine. Vaccine 22: 1275–1280.
Suaya JA, Shepard DS, Chang MS, Caram M, Hoyer S, Socheat D, Chantha N, Nathan MB, 2007. Cost-effectiveness of annual targeted larviciding campaigns in Cambodia against the dengue vector Aedes aegypti. Trop Med Int Health 12: 1026–1036.
Suaya JA, Shepard DS, Siqueira JB, Martelli CT, Lum LC, Tan LH, Kongsin S, Jiamton S, Garrido F, Montoya R, Armien B, Huy R, Castillo L, Caram M, Sah BK, Sughayyar R, Tyo KR, Halstead SB, 2009. Cost of dengue cases in eight countries in the Americas and Asia: a prospective study. Am J Trop Med Hyg 80: 846–855.
Torres MI, 1997. Impact of an outbreak of dengue fever: a case study from rural Puerto Rico. Hum Organ 56: 19–27.
Tun-Lin W, Lenhart A, Nam VS, Rebollar-Téllez E, Morrison AC, Barbazan P, Cote M, Midega J, Sanchez F, Manrique-Saide P, Kroeger A, Nathan MB, Meheus F, Petzold M, 2009. Reducing costs and operational constraints of dengue vector control by targeting productive breeding places: a multi-country non-inferiority cluster randomized trial. Trop Med Int Health 14: 1143–1153.
Valdés L, Vila J, Guzmán MG, 2002. Economic impact of the dengue 2 epidemic in Santiago of Cuba, 1997 [Spanish]. Rev Cubana Med Trop 54: 220–227.
Van Damme W, Van Leemput L, Por I, Hardeman W, Meessen B, 2004. Out-of-pocket health expenditure in poor households: evidence from Cambodia. Trop Med Int Health 9: 273–280.
Von Allmen SD, López-Correa RH, Woodall JP, Morens DM, Chiriboga J, Casta-Velez A, 1979. Epidemic dengue fever in Puerto Rico, 1977: a cost analysis. Am J Trop Med Hyg 28: 1040–1044.
Wong CY, Wu E, Wong TY, 2007. Examining the effect of publishing of bill sizes to reduce information asymmetry on healthcare costs. Singapore Med J 48: 16–24.
World Health Organization, 1996. The global burden of disease. A comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 and projected to 2020. Murray CJ, Lopez LD, Mathers CD, eds. Global Burden of Disease and Injury Series, Volume I. Atlanta, GA: World Health Organization.
World Health Organization, 1996. Global health statistics. A compendium of incidence, prevalence, and mortality estimates for over 200 conditions. Murray CJ, Lopez LD, eds. Global Burden of Disease and Injury Series, Volume II. Atlanta, GA: World Health Organization.
World Health Organization, 2008. The global burden of disease: 2004 update. Available at: www.who.int/healthinfo/global_burden_disease/2004_report_update/en/index.html. Accessed January 22, 2010.
Pan American Health Organization, 1997. Dengue and dengue hemorrhagic fever in the Americas. Washington, DC: Pan American Health Organization. Available at: http://www.paho.org/English/ad/dpc/cd/dengue.html. Accessed January 22, 2010.
Endy TP, Chunsuttiwat S, Nisalak A, Libraty DH, Green S, Rothman AL, Vaughn DW, Ennis FA, 2002. Epidemiology of inapparent and symptomatic acute dengue virus infection: a prospective study of primary school children in Kamphaeng Phet, Thailand. Am J Epidemiol 156: 40–51.
Porter KR, Beckett CG, Kosasih H, Tan RI, Alisjahbana B, Rudiman PI, Widjaja S, Listiyaningsih E, Ma'Roef CN, McArdle JL, Parwati I, Sudjana P, Jusuf H, Yuwono D, Wuryadi S, 2005. Epidemiology of dengue and dengue hemorrhagic fever in a cohort of adults living in Bandung, West Java, Indonesia. Am J Trop Med Hyg 72: 60–66.
Graham RR, Juffrie M, Tan R, Hayes CG, Laksono I, Ma'roef C, Erlin Sutaryo, Porter KR, Halstead SB, 1999. A prospective seroepidemiologic study on dengue in children four to nine years of age in Yogyakarta, Indonesia I. Studies in 1995–1996. Am J Trop Med Hyg 61: 412–419.
Mathers CD, Ezzati M, Lopez AD, 2007. Measuring the burden of neglected tropical diseases: the global burden of disease framework. PLoS Negl Trop Dis 1: e114.
Neff JM, Morris L, Gonzalez-Alcover R, Coleman PH, Lyss SB, Negron H, 1967. Dengue fever in a Puerto Rican community. Am J Epidemiol 86: 162–184.
Dechant EJ, Rigau-Pérez JG, 1999. Hospitalizations for suspected dengue in Puerto Rico, 1991–1995: estimation by capture-recapture methods. Am J Trop Med Hyg 61: 574–578.
Chareonsook O, Foy HM, Teeraratkul A, Silarug N, 1999. Changing epidemiology of dengue hemorrhagic fever in Thailand. Epidemiol Infect 122: 161–166.
Sharma SK, 1998. Entomological investigations of DF/DHF outbreak in rural areas of Hissar District, Haryana, India. Dengue Bull 22: 36–41.
Lian CW, Seng CM, Chai WY, 2006. Spatial, environmental and entomological risk factor analysis on a rural dengue outbreak in Lundu District in Sarawak, Malaysia. Trop Biomed 23: 85–96.
World Health Organization, 2005. World Health Survey. Geneva: World Health Organization. Available at: http://www.who.int/healthinfo/survey/en/index.html. Accessed February 10, 2010.
EuroQol Group, 1990. EuroQol–a new facility for the measurement of health-related quality of life. Health Policy Plan 16: 199–208.
Griebsch I, Coast J, Brown J, 2005. Quality-adjusted life-years lack quality in pediatric care: a critical review of published cost-utility studies in child health. Pediatrics 115: e600–e614.
Kittigul L, Pitakarnjanakul P, Sujirarat D, Siripanichgon K, 2007. The differences of clinical manifestations and laboratory findings in children and adults with dengue virus infection. J Clin Virol 39: 76–81.
Egger JD, Coleman PG, 2007. Age and clinical dengue illness. Emerg Infect Dis 13: 924–925.
Adam T, Evans DB, Murray CJ, 2003. Econometric estimation of country-specific hospital costs. Cost Eff Resour Alloc 1: 3.
Guzman MG, Kouri G, 2003. Dengue and dengue hemorrhagic fever in the Americas: lessons and challenges. J Clin Virol 27: 1–13.
Siqueira JB Jr, Martelli CM, Coelho GE, Simplicio AC, Hatch DL, 2005. Dengue and dengue hemorrhagic fever, Brazil, 1981–2002. Emerg Infect Dis 11: 48–53.
Kabilan L, 2004. Control of Japanese encephalitis in India: a reality. Indian J Pediatr 71: 707–712.
World Health Organization, 2009. Yellow fever. Geneva: World Health Organization. Available at: http://www.who.int/mediacentre/factsheets/fs100/en/. Accessed January 22, 2010.
Pickford-Gordon L, 2008. Year of dengue outbreaks. Trinidad and Tobago Newsday. Available at: http://www.newsday.co.tt/news/0.htmlhttp://www.newsday.co.tt/news/92520.html. Accessed January 22, 2010.
World Health Organization, 1997. Emergency preparation and response. Dengue Hemorrhagic Fever: Diagnosis, Treatment, Prevention and Control. Second edition. Geneva: World Health Organization.
Griffiths UK, Hutton G, Das Dores Pascoal E, 2005. The cost-effectiveness of introducing hepatitis B vaccine into infant immunization services in Mozambique. Health Policy Plan 20: 50–59.
Thiry N, Beutels P, Tancredi F, Romanò L, Zanetti A, Bonanni P, Gabutti G, Van Damme P, 2004. An economic evaluation of varicella vaccination in Italian adolescents. Vaccine 22: 3546–3562.
Mahoney R, Maynard J, 1999. The introduction of new vaccines into developing countries. Vaccine 17: 646–652.
Gupta E, Dar L, Kapoor G, Broor S, 2006. The changing epidemiology of dengue in Delhi, India. Virol J 3: 92.
Nisalak A, Endy TP, Nimmannitya S, Kalayanarooj S, Thisayakorn U, Scott RM, Burke DS, Hoke CH, Innis BL, Vaughn DW, 2003. Serotype-specific dengue virus circulation and dengue disease in Bangkok, Thailand from 1973 to 1999. Am J Trop Med Hyg 68: 191–202.
Xu K, Evans DB, Kawabata K, Zeramdini R, Klavus J, Murray CJ, 2003. Household catastrophic health expenditure: a multicountry analysis. Lancet 362: 111–117.
Flores G, Krishnakumar J, O'Donnell O, van Doorslaer E, 2008. Coping with health-care costs: implications for the measurement of catastrophic expenditures and poverty. Health Econ 17: 1393–1412.
Sauerborn R, Nougtara A, Hien M, Diesfeld HJ, 1996. Seasonal variations of household costs of illness in Burkina Faso. Soc Sci Med 43: 281–290.
Winch PJ, Makemba AM, Kamazima SR, Lwihula GK, Lubega P, Minjas JN, Shiff CJ, 1994. Seasonal variation in the perceived risk of malaria: implications for the promotion of insecticide-impregnated bed nets. Soc Sci Med 39: 63–75.
World Health Organization, 2008. WHO guide for standardization of economic evaluations of immunization programmes. WHO/IVB/08.14. Geneva: World Health Organization.
World Health Organization, 2009. WHO Guide to Indentifying the Economic Consequences of Disease and Injury. Geneva: World Health Organization.
Scott TW, Morrison AC, 2004. Aedes aegyptidensity and the risk of dengue-virus transmission. Takken W, Scott TW, eds. Ecological Aspects for Application of Genetically Modified Mosquitoes. Dordrecht, the Netherlands: Kluwer Academic Publishers.
Sanchez L, Vanlerberghe V, Alfonso L, Marquetti Mdel C, Guzman MG, Bisset J, van der Stuyft P, 2006. Aedes aegypti larval indices and risk for dengue epidemics. Emerg Infect Dis 12: 800–806.
Hanemann WM, 1994. Valuing the environment through contingent valuation. J Econ Perspect 8: 19–43.
2007. Paraguay dengue official sacked. Available at: http://news.bbc.co.uk/2/hi/americas/6422319.stm. Accessed January 22, 2010.
2007. Top Tainan [China] health official sacked over dengue spread. China Times. Available at: http://www.chinapost.com.tw/taiwan/2007/08/29/120392/Top-Tainan.htm. Accessed January 22, 2010.
2007. Dengue officials may be fired [Cebu, Philippines]. Daily News [Philippines]. Available at: http://globalnation.inquirer.net/cebudailynews/news/view/20071221-108175/Dengue_officials_may_be_fired. Accessed January 22, 2010.
Siang LK, 2003. Worst dengue epidemic–nation-wide campaign to demand resignation of Health Minister Chua Jui [Singapore]. Democratic Action Party. Available at: http://www.limkitsiang.com/archive/2003/jan03/lks2052.htm. Accessed January 22, 2010.
Advisory Committee on Immunization Practices, 2004. Meningococcal disease and college students. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 49: 13–22.
Welte R, Trotter C, Edmunds WJ, Postma M, Beutels P, 2005. The role of economic evaluation in vaccine decision making: focus on meningococcal C vaccination. Pharmacoeconomics 23: 855–874.
World Health Organization, 2009. Dengue guidelines for diagnosis, treatment, prevention and control. WHO/HTM/NTD/DEN/2009.1. Available at: http://whqlibdoc.who.int/publications/2009/9789241547871_eng.pdf. Accessed 2010 May 17.
Deen JL, Harris E, Wills B, Balmaseda A, Hammond SN, Rocha C, Dung NM, Hung NT, Hien TT, Farrar JJ, 2006. The WHO dengue classification and case definitions: time for a reassessment. Lancet 368: 170–173.
Johns B, Baltussen R, Hutubessy R, 2003. Programme costs in the economic evaluation of health interventions. Cost Eff Resour Alloc 1: 1.
Kim SY, Goldie SJ, 2008. Cost-effectiveness analyses of vaccination programmes: a focused review of modelling approaches. Pharmacoeconomics 26: 191–215.
Meltzer MI, Cox NJ, Fukuda K, 1999. The economic impact of pandemic influenza in the United States: priorities for intervention. Emerg Infect Dis 5: 659–671.
|Past two years||Past Year||Past 30 Days|
|Full Text Views||1038||335||3|
Dengue vaccines are currently in development and policymakers need appropriate economic studies to determine their potential financial and public health impact. We searched five databases (PubMed, EMBASE, LILAC, EconLit, and WHOLIS) to identify health economics studies of dengue. Forty-three manuscripts were identified that provided primary data: 32 report economic burden of dengue and nine are comparative economic analyses assessing various interventions. The remaining two were a willingness-to-pay study and a policymaker survey. An expert panel reviewed the existing dengue economic literature and recommended future research to fill information gaps. Although dengue is an important vector-borne disease, the economic literature is relatively sparse and results have often been conflicting because of use of inconsistent assumptions. Health economic research specific to dengue is urgently needed to ensure informed decision making on the various options for controlling and preventing this disease.
Financial support: PDVI is funded solely by The Bill and Melinda Gates Foundation (www.gatesfoundation.org). The systematic review was completed as part of the routine work of PDVI. The donor had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Disclosure: LC is an employee of Sanofi Pasteur, a company that is currently developing a dengue vaccine. This statement is made in the interest of full disclosure and not because the authors consider this to be a conflict of interest.
Authors' addresses: Mark E. Beatty, International Vaccine Institute, Seoul, Korea, E-mail: firstname.lastname@example.org. Philippe Beutels, Centre for Health Economics Research and Modeling Infectious Diseases (CHERMID), Centre for the Evaluation of Vaccination (CEV), Vaccine and Infectious Disease Institute (VAXINFECTIO), University of Antwerp, Antwerp, Belgium, E-mail: email@example.com. Martin I. Meltzer, U.S. Centers for Disease Control and Prevention, CDC/CCID/NCPDCID/DEISS, Atlanta, GA, E-mail: qzm4@CDC.GOV. Donald S. Shepard, Schneider Institutes for Health Policy, Heller School, Brandeis University, Waltham, MA, E-mail: firstname.lastname@example.org. Joachim Hombach and Raymond Hutubessy, Initiative for Vaccine Research (IVR), World Health Organization, Geneva, Switzerland, E-mails: email@example.com and firstname.lastname@example.org. Damien Dessis, GlaxoSmithKline Biologicals, Wavre, Belgium, E-mail: email@example.com. Laurent Coudeville, Sanofi Pasteur, Lyon, France, E-mail: firstname.lastname@example.org. Benoit Dervaux, Université Catholique de Lille, Lille, France, E-mail: email@example.com. Ole Wichmann, Robert Koch-Institute, Berlin, Germany, E-mail: WichmannO@rki.de. Harold S. Margolis, Centers for Disease Control and Prevention, Dengue Branch, Calle Cañada, San Juan, Puerto Rico, E-mail: firstname.lastname@example.org. Joel N. Kuritsky, United States Agency for International Development, Ronald Reagan Building, Washington, DC, E-mail: email@example.com.